Key points are not available for this paper at this time.
mutations. Adjuvant imatinib improves OS substantially if high-risk GISTs can be identified, treatment duration is long enough, and GISTs harbor an imatinib-sensitive mutation.
Heikki Joensuu (2023) studied this question.